SG11201900745VA - Substituted thiazolo-pyridine compounds as malt1 inhibitors - Google Patents

Substituted thiazolo-pyridine compounds as malt1 inhibitors

Info

Publication number
SG11201900745VA
SG11201900745VA SG11201900745VA SG11201900745VA SG11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA SG 11201900745V A SG11201900745V A SG 11201900745VA
Authority
SG
Singapore
Prior art keywords
nande
pune
village
taluka
mulshi
Prior art date
Application number
SG11201900745VA
Inventor
Gagan Kukreja
Nageswara Irlapati
Arun Jagdale
Gokul Deshmukh
Vinod Vyavahare
Kiran Kulkarni
Neelima Sinha
Venkata Palle
Rajender Kamboj
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of SG11201900745VA publication Critical patent/SG11201900745VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

International Patent Classification: CO7D 513/04 (2006.01) A61P 37/00 A61K 31/429 (2006.01) A61P 17/00 A61P 35/00 (2006.01) A61P 19/00 (2006.01) (2006.01) (2006.01) (21) International Application Number: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 February 2018 (01.02.2018) WIPO I PCT °mons °nolo ovum Mo mo mnio oimIE (10) International Publication Number WO 2018/020474 Al PCT/IB2017/054612 (22) International Filing Date: 28 July 2017 (28.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201621026107 29 July 2016 (29.07.2016) IN (71) Applicant: LUPIN LIMITED [IN/IN]; Kalpataru Inspire, 3rd Floor, Off Western Express Highway, Santacruz (East), Maharashtra, Mumbai 400 055 (IN). (72) Inventors: KUKREJA, Gagan; Lupin Limited (Research Park), 46A / 47A Village Nande, Taluka Mulshi, Ma- harashtra, Pune 412115 (IN). IRLAPATI, Nageswara, Rao; Lupin Limited (Research Park), 46A / 47A Village Nande, Taluka Mulshi, Maharashtra, Pune 412115 (IN). JAGDALE, Arun, Rangnath; Lupin Limited (Research Park), 46A / 47A Village Nande, Taluka Mulshi, Maha- rashtra, Pune 412115 (IN). DESHMUKH, Gokul, Keru- ji; Lupin Limited (Research Park), 46A / 47A Village Nande, Taluka Mulshi, Maharashtra, Pune 412115 (IN). VYAVAHARE, Vinod, Popatrao; Lupin Limited (Re- search Park), 46A / 47A, Village Nande, Taluka Mul- shi, Maharashtra, Pune 412115 (IN). KULKARNI, Kiran, Chandrashekhar; Lupin Limited (Research Park), 46A / 47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 412115 (IN). SINHA, Neelima; Lupin Limited (Research Park), 46A / 47A, Village Nande, Taluka Mulshi, Maha- rashtra, Pune 412115 (IN). PALLE, Venkata, P.; Lupin Limited (Research Park), 46A / 47A, Village Nande, Talu- ka Mulshi, Maharashtra, Pune 412115 (IN). KAMBOJ, Rajender, Kumar; Lupin Limited (Research Park), 46A / 47A, Village Nande, Taluka Mulshi, Maharashtra, Pune 412115 (IN). (74) Agent: MAJUMDAR, Subhatosh et al.; S. Majumdar & Co., 5 Harish Mukherjee Road, State of West Bengal, Kolkata 700 025 (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) 1-1 7 1 - (54) Title: SUBSTITUTED THIAZOLO-PYRIDINE COMPOUNDS AS MALT1 INHIBITORS O 71' O O C R 2 H H R' ° (I) (57) : Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammato- ry diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also dis- closed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
SG11201900745VA 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors SG11201900745VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201621026107 2016-07-29
PCT/IB2017/054612 WO2018020474A1 (en) 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201900745VA true SG11201900745VA (en) 2019-02-27

Family

ID=59745317

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900745VA SG11201900745VA (en) 2016-07-29 2017-07-28 Substituted thiazolo-pyridine compounds as malt1 inhibitors

Country Status (15)

Country Link
US (1) US20190275012A9 (en)
JP (1) JP2019522035A (en)
KR (1) KR20190033607A (en)
CN (1) CN110312724A (en)
AU (1) AU2017302182B2 (en)
CA (1) CA3032334A1 (en)
CL (1) CL2019000221A1 (en)
DO (1) DOP2019000020A (en)
IL (1) IL289474A (en)
MX (1) MX2019001132A (en)
PE (1) PE20190656A1 (en)
PH (1) PH12019500214A1 (en)
RU (1) RU2019104890A (en)
SG (1) SG11201900745VA (en)
WO (1) WO2018020474A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11248007B2 (en) 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof
JP7271540B2 (en) * 2017-11-17 2023-05-11 へパジーン セラピューティクス （エイチケイ） リミテッド Urea derivatives as ASK1 inhibitors
MX2020013699A (en) * 2018-06-18 2021-05-12 Janssen Pharmaceutica Nv Pyrazole derivatives as malt1 inhibitors.
US11040031B2 (en) * 2018-06-18 2021-06-22 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
CN109265453A (en) * 2018-10-23 2019-01-25 华侨大学 It is a kind of as the semicarbazones analog derivative of caspase-3 activator and its application
BR112021009994A2 (en) * 2018-11-28 2021-08-17 Takeda Pharmaceutical Company Limited compound and medicine
MX2021012417A (en) 2019-04-11 2021-11-12 Janssen Pharmaceutica Nv Pyridine rings containing derivatives as malt1 inhibitors.
WO2021000855A1 (en) * 2019-07-01 2021-01-07 Qilu Regor Therapeutics Inc. Malt1 inhibitors and uses thereof
WO2021063735A1 (en) * 2019-10-02 2021-04-08 Basf Se New bicyclic pyridine derivatives
EP4081526A1 (en) * 2019-12-27 2022-11-02 Schrödinger, Inc. Cyclic compounds and methods of using same
JPWO2021241611A1 (en) * 2020-05-27 2021-12-02
US20230235077A1 (en) 2020-06-24 2023-07-27 The General Hospital Corporation Materials and methods of treating cancer
JP2023549835A (en) * 2020-11-12 2023-11-29 モノプテロス セラピューティクス，インコーポレーテッド Materials and methods for treating cancer
WO2023148501A1 (en) 2022-02-03 2023-08-10 C4X Discovery Limited Heterocyclic derivatives as malt1 inhibitors
TW202345806A (en) 2022-03-31 2023-12-01 美商艾伯維有限公司 Thiazolo[5,4-b]pyridine malt-1 inhibitors
WO2023192506A1 (en) * 2022-03-31 2023-10-05 Rarified Biosciences, Inc. Malt1 modulators and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
CN1414848A (en) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Prevention of plaque rupure by ACAT inhibitors
AU2003222667A1 (en) * 2002-04-23 2003-11-10 Chugai Seiyaku Kabushiki Kaisha 1,3-thiazoles as lxr modulators in the treatment of cardiovascular diseases
EP2153231B1 (en) 2007-06-01 2013-05-15 University of Lausanne Malt1 specific cleavage in assay and screening method
ATE553769T1 (en) 2007-11-21 2012-05-15 Vib Vzw INHIBITORS OF MALT1 PROTEOLYTIC ACTIVITY AND THEIR USE
WO2013013816A1 (en) * 2011-07-26 2013-01-31 Grünenthal GmbH Substituted bicyclic aromatic carboxamide and urea derivatives as vanilloid receptor ligands
JP6069321B2 (en) * 2011-08-02 2017-02-01 ヘルムホルツ ツェントラム ミュンヘン ドイチェス フォーシュングスツェントラム フュール ゲズントハイト ウント ウンヴェルト ゲーエムベーハーＨｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ Ｍｕｅｎｃｈｅｎ Ｄｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ Ｕｎｄ Ｕｍｗｅｌｔ Ｇｍｂｈ Selective inhibition of MALT1 protease by phenothiazine derivatives
WO2013053765A1 (en) 2011-10-11 2013-04-18 Proyecto De Biomedicina Cima, S.L. A non-human animal model of mucosa-associated lymphoid tissue (malt) lymphoma
US9592223B2 (en) 2012-11-09 2017-03-14 Cornell University Small molecule inhibitors of MALT1
WO2014086478A1 (en) * 2012-12-03 2014-06-12 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of malt1 protease
US9718811B2 (en) 2013-06-26 2017-08-01 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (S)-enantiomer of mepazine
EP3097124B1 (en) 2014-01-21 2018-12-19 Helmholtz Zentrum München Means and methods for detecting activated malt1
EP3149001B1 (en) * 2014-05-28 2019-04-24 Novartis AG Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
DE102015210224A1 (en) 2015-06-02 2016-12-08 Universitätsklinikum Hamburg-Eppendorf NEW ACTIVE FOR THE TREATMENT OF CANCER
WO2017040304A1 (en) 2015-08-28 2017-03-09 Cornell University Malt1 inhibitors and uses thereof
JPWO2017057695A1 (en) 2015-09-30 2018-07-19 東レ株式会社 Diphenylpyrazole derivatives and their pharmaceutical use
JP2018533610A (en) 2015-11-13 2018-11-15 ノバルティス アーゲー Novel pyrazolo pyrimidine derivatives
US11248007B2 (en) * 2017-03-08 2022-02-15 Cornell University Inhibitors of MALT1 and uses thereof

Also Published As

Publication number Publication date
US20190160045A1 (en) 2019-05-30
PH12019500214A1 (en) 2019-10-28
KR20190033607A (en) 2019-03-29
PE20190656A1 (en) 2019-05-08
JP2019522035A (en) 2019-08-08
MX2019001132A (en) 2019-12-16
CN110312724A (en) 2019-10-08
RU2019104890A3 (en) 2020-08-31
IL289474A (en) 2022-02-01
AU2017302182A1 (en) 2019-03-07
CA3032334A1 (en) 2018-02-01
CL2019000221A1 (en) 2019-06-07
US20190275012A9 (en) 2019-09-12
DOP2019000020A (en) 2019-04-30
WO2018020474A1 (en) 2018-02-01
RU2019104890A (en) 2020-08-31
AU2017302182B2 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809301YA (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201901548SA (en) Anti-tim-3 antibodies and use thereof
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201808990QA (en) Compositions for topical application of compounds
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408780XA (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201901597UA (en) Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
SG11201903786UA (en) Farnesyltransferase inhibitors for use in methods of treating cancer